Lumos Pharma (NASDAQ:LUMO) Rating Increased to Strong-Buy at EF Hutton Acquisition Co. I

Lumos Pharma (NASDAQ:LUMO) was upgraded by equities researchers at EF Hutton Acquisition Co. I to a “strong-buy” rating in a research note issued on Tuesday, Zacks.com reports.

Separately, Oppenheimer reduced their price objective on Lumos Pharma from $16.00 to $13.00 and set an “outperform” rating on the stock in a research note on Friday, August 2nd.

Lumos Pharma Stock Down 5.2 %

NASDAQ:LUMO opened at $3.84 on Tuesday. The company has a market cap of $31.18 million, a P/E ratio of -0.84 and a beta of 0.78. The firm’s 50 day moving average is $2.98 and its two-hundred day moving average is $2.68. Lumos Pharma has a fifty-two week low of $1.37 and a fifty-two week high of $4.55.

Lumos Pharma (NASDAQ:LUMO) last issued its earnings results on Thursday, August 1st. The company reported ($0.93) earnings per share for the quarter, topping the consensus estimate of ($1.26) by $0.33. Lumos Pharma had a negative return on equity of 157.99% and a negative net margin of 2,405.72%. The business had revenue of $0.49 million for the quarter. During the same period last year, the business posted ($1.09) earnings per share. Research analysts forecast that Lumos Pharma will post -2.56 earnings per share for the current fiscal year.

Lumos Pharma Company Profile

Lumos Pharma, Inc, a clinical-stage biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of products and therapies for people with rare diseases. Its primary product candidate is LUM-201, an oral growth hormone secretagogue ibutamoren, which is in Phase III clinical trial for the treatment of idiopathic pediatric growth hormone deficiency and other rare endocrine disorders.